Micro Array Analysis in Preeclampsia

Study Overview
=================
Brief Summary
-----------------
Preeclampsia is a frequent pathology. His etiology is doubtful. Targets : The study target is to identify a risk of preeclampsia group obtained with transcriptom analysis from circulating peripheric cells. Design: Multidisciplinary study (Gynaecology-Obstetric, Immunology, North CIC). The study of the transcriptional history of peripheral blood cells of 2patients groups: A patient group with a preeclampsia before 34 SA A patient group with a normal pregnancy paired on main confusion factors. Blood sampling will be collected at the diagnosis and 8 weeks after delivery. Results and perspectives Obtain a transcriptionnal signature of preeclampsia To identify new mechanism of the disease Identification of a specific transcriptom analysis with the comparison after delivery For long-term, the target is to identify risk patient in order to conduct easily preventive clinical trials in preeclamsia (primary prevention) and to consider a specific follow-up for risk patients.

Official Title
-----------------
Micro Array Analysis in Preeclampsia

Conditions
-----------------
Preeclampsia

Intervention / Treatment
-----------------
* Other: samples blood
* Other: biopsy placentaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A prééclampsie (blood pressure superior to 140 mmHg and to 90 mmHg) and at least a cross of protein in the strip and/or more of 300mg / 24h after 20 LIMITED COMPANIES and before 34 limited companies. An informed consent signed by the patient will necessarily have to be obtained. Woman having been taken care during the pregnancy or at the time of the childbirth(delivery) by one of the participating teams to the current project. Caucasian Patient Wait primigeste and nullipare Exclusion Criteria: Major Patient protected by the law. Patient deprived of freedom for administrative or judicial reasons. Patient not benefiting from a national insurance scheme. Refusal of the patient to participate in the study. Not Caucasian Patient Multipare Wait Multiple Pregnancy Existence of foetal deformation explaining a delay of growth or a foetal death in utero. Age 18 years and > 40 years. Absence of written consent or impossibility to receive the written consent (language or understanding).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: group with a preeclampsia before 34 SA<br> | Other: samples blood<br> <br> Other: biopsy placentaire<br> <br> |
| Other: group with a normal pregnancy<br> | Other: samples blood<br> <br> Other: biopsy placentaire<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| predictive markers of preeclampsia | blood samples | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| analysis of placental transcriptional profile. | biopsie placentaire | 36 months |